Propel Bio Management 13F annual report
Propel Bio Management is an investment fund managing more than $172 billion ran by Jim Harding. There are currently 28 companies in Mr. Harding’s portfolio. The largest investments include Applied Therapeutics and Plains Gp Holdings Lp-cl, together worth $69.5 billion.
$172 billion Assets Under Management (AUM)
As of 5th August 2024, Propel Bio Management’s top holding is 6,111,906 shares of Applied Therapeutics currently worth over $41.6 billion and making up 24.2% of the portfolio value.
Relative to the number of outstanding shares of Applied Therapeutics, Propel Bio Management owns more than 0.1% of the company.
In addition, the fund holds 1,492,581 shares of Plains Gp Holdings Lp-cl worth $28 billion.
The third-largest holding is Tscan Therapeutics Inc worth $16.6 billion and the next is Madrigal Pharmaceuticals Inc worth $11.5 billion, with 43,032 shares owned.
Currently, Propel Bio Management's portfolio is worth at least $172 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Propel Bio Management
The Propel Bio Management office and employees reside in Los Angeles, California. According to the last 13-F report filed with the SEC, Jim Harding serves as the Finance Director at Propel Bio Management.
Recent trades
In the most recent 13F filing, Propel Bio Management revealed that it had opened a new position in Applied Therapeutics and bought 6,111,906 shares worth $41.6 billion.
One of the smallest hedge funds
The two most similar investment funds to Propel Bio Management are Marvin & Palmer Associates Inc and Alibaba Ltd. They manage $154 billion and $154 billion respectively.
Jim Harding investment strategy
Propel Bio Management’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 67.3% of
the total portfolio value.
The fund focuses on investments in the United States as
60.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
21% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $539 million.
The complete list of Propel Bio Management trades based on 13F SEC filings
These positions were updated on August 12th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Applied Therapeutics, Inc. |
Opened
6,111,906
|
$41,560,961,000 | 24.19% |
| Plains Gp Holdings Lp-cl |
Opened
1,492,581
|
$27,978,962,000 | 16.29% |
| Tscan Therapeutics Inc |
Opened
2,087,139
|
$16,571,884,000 | 9.65% |
| Madrigal Pharmaceuticals Inc |
Opened
43,032
|
$11,491,265,000 | 6.69% |
| Achieve Life Sciences Inc. |
Opened
2,453,092
|
$11,149,303,000 | 6.49% |
| Phathom Pharmaceuticals Inc |
Opened
869,927
|
$9,238,625,000 | 5.38% |
| Akero Therapeutics Inc |
Opened
327,752
|
$8,279,016,000 | 4.82% |
| Fulcrum Therapeutics Inc |
Opened
750,000
|
$7,080,000,000 | 4.12% |
| Avidity Biosciences, Inc. |
Opened
178,500
|
$4,555,320,000 | 2.65% |
| Day One Biopharmaceuticals I |
Opened
270,664
|
$4,471,369,000 | 2.60% |
| Ardelyx Inc |
Opened
594,174
|
$4,337,470,000 | 2.52% |
| Athira Pharma, Inc. |
Opened
1,492,792
|
$4,090,250,000 | 2.38% |
| Kura Oncology Inc |
Opened
130,000
|
$2,772,900,000 | 1.61% |
| Telesat Corp |
Opened
290,781
|
$2,500,717,000 | 1.46% |
| Kymera Therapeutics, Inc. |
Opened
56,359
|
$2,265,632,000 | 1.32% |
| iShares MBS ETF |
Opened
22,400
|
$2,070,208,000 | 1.20% |
| Syndax Pharmaceuticals Inc |
Opened
83,259
|
$1,981,564,000 | 1.15% |
| Mirum Pharmaceuticals Inc |
Opened
70,000
|
$1,758,400,000 | 1.02% |
| Marinus Pharmaceuticals Inc |
Opened
180,100
|
$1,628,104,000 | 0.95% |
| Kayne Anderson Energy Inf |
Opened
147,033
|
$1,471,800,000 | 0.86% |
| Sutro Biopharma Inc |
Opened
195,000
|
$1,101,750,000 | 0.64% |
| Trevi Therapeutics, Inc. |
Opened
260,000
|
$897,000,000 | 0.52% |
| X4 Pharmaceuticals, Inc. |
Opened
535,000
|
$743,650,000 | 0.43% |
| Eiger BioPharmaceuticals Inc |
Opened
146,381
|
$731,905,000 | 0.43% |
| Ishares Iboxx Investment |
Opened
4,456
|
$485,348,000 | 0.28% |
| Cybin Inc |
Opened
850,000
|
$351,475,000 | 0.20% |
| Fidelity Inv Mmtrsy 1 680 |
Opened
211,541
|
$211,541,000 | 0.12% |
| Chinook Therapeutics Inc Cvr |
Opened
79,357
|
$30,949,000 | 0.02% |
| No transactions found | |||
| Showing first 500 out of 28 holdings | |||
Hedge funds similar to Propel Bio Management
- Sqn Investors L.P.
- Mendel Capital Management
- Boomfish Wealth
- Corrado Advisors
- Yoder Wealth Management
- 22nw, L.P.
- Cohen Investment Advisors
- Marvin & Palmer Associates Inc
- Alibaba Ltd
- Otter Creek Advisors
- Cobblestone Asset Management
- Acuta Capital Partners
- General Motors
- Entrust Global Partners L L C